HRP20170154T1 - Analozi antibakterijskog aminoglikozida - Google Patents

Analozi antibakterijskog aminoglikozida Download PDF

Info

Publication number
HRP20170154T1
HRP20170154T1 HRP20170154TT HRP20170154T HRP20170154T1 HR P20170154 T1 HRP20170154 T1 HR P20170154T1 HR P20170154T T HRP20170154T T HR P20170154TT HR P20170154 T HRP20170154 T HR P20170154T HR P20170154 T1 HRP20170154 T1 HR P20170154T1
Authority
HR
Croatia
Prior art keywords
hydroxy
amino
sisomycin
hydrogen
compound
Prior art date
Application number
HRP20170154TT
Other languages
English (en)
Inventor
James Aggen
Adam Aaron Goldblum
Martin Linsell
Paola Dozzo
Heinz Ernst Moser
Darin Hildebrandt
Micah Gliedt
Original Assignee
Achaogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achaogen, Inc. filed Critical Achaogen, Inc.
Publication of HRP20170154T1 publication Critical patent/HRP20170154T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/224—Cyclohexane rings substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexyl radical, e.g. destomycin, fortimicin, neamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
    • C07H15/236—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 a saccharide radical being substituted by an alkylamino radical in position 3 and by two substituents different from hydrogen in position 4, e.g. gentamicin complex, sisomicin, verdamycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (25)

1. Spoj, naznačen time, da ima sljedeću strukturu (I): [image] ili stereoizomer, farmaceutski prihvatljiva sol, pri čemu: Q1 je vodik, [image] Q2 je vodik, po izboru supstituirani aril, po izboru supstituirani aralkil, po izboru supstituirani cikloalkil, po izboru supstituirani cikloalkilalkil, po izboru supstituirani hetcrociklil, po izboru supstituirani hetcrociklilalkil, po izboru supstituirani heteroaril, po izboru supstituirani hetcroarilalkil, -C(=NH)NR4R5, (CR10R11)pR12, [image] Q3 je vodik, po izboru supstituirani aril, po izboru supstituirani aralkil, po izboru supstituirani cikloalkil, po izboru supstituirani cikloalkilalkil, po izboru supstituirani hetcrociklil, po izboru supstituirani heterociklilalkil, po izboru supstituirani heteroaril, po izboru supstituirani heteroarilalkil, -C(=NH)NR4R5, (CR10R11)pR12, [image] svaki R1, R2, R3, R4, R5, R8 and R10 je, neovisno, vodik ili C1-C6 alkil ili R1 i R2 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena ili R1 i R3 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena ili R1 i R3 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena ili R4 i R5 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena; svaki R6 i R7 je, neovisno, vodik, hidroksil, amino ili C1-C6 alkil ili R6 i R7 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena; svaki R9 je, neovisno, vodik ili metil; svaki R11 je, neovisno, vodik, hidroksil, amino ili C1-C6 alkil; svaki R12 je, neovisno, hidroksil ili amino; svaki n je, neovisno, cijeli broj od 0 do 4; svaki m je, neovisno, cijeli broj od 0 do 4 i svaki p je, neovisno, cijeli broj od 1 do 5 a pri čemu je (i) najmanje dva od Q1 Q2i Q3 su drugačiji od vodika i (ii) ako Q1, je vodik, tada najmanje jedan od Q2 i Q3 je -C(=NH)N R4R5.
2. Spoj iz patentnog zahtjeva 1, naznačen time, da je R8 vodik.
3. Spoj iz patentnog zahtjeva 1 ili 2, naznačen time, da je svaki R9 metil.
4. Spoj prema bilo koje od patentnih zahtjeva 1-3, naznačen time, da Q1 i Q2 nisu vodik.
5. Spoj iz patentnog zahtjeva 4, naznačen time, da je Q3 vodik.
6. Spoj iz patentnog zahtjeva 4 ili 5, naznačen time, da je Q1: [image] pri čemu: R1 je vodik; R2 je vodik i svaki R3 je vodik.
7. Spoj iz patentnog zahtjeva 6, naznačen time da je Q1 [image]
8. Spoj iz patentnog zahtjeva 4 ili 5, naznačen time da je Q1: [image] pri čemu: R1 je vodik; i R2 i R3 zajedno s atomima za kojih su vezani tvore heterociklički prsten koji ima od 4 do 6 atoma prstena.
9. Spoj iz patentnog zahtjeva 4 ili 5, naznačen time da je Q1: [image] pri čemu: R3 je vodik; i R1 i R2 zajedno s atomima za kojih su vezani tvore heterociklički prsten koji ima od 4 do 6 atoma prstena.
10. Spoj iz patentnog zahtjeva 4 ili 5, naznačen time da je Q1: [image] pri čemu: R2 je vodik; i R1 i R3 zajedno s atomima za koje su vezani tvore karbociklički prsten koji ima od 4 do 6 atoma prstena.
11. Spoj iz patentnog zahtjeva 4 ili 5, naznačen time da je Q1: [image] pri čemu: R2 je vodik; i svaki R3 je vodik.
12. Spoj iz patentnog zahtjeva 4 ili 5, naznačen time da je Q1: [image] pri čemu: R2 je vodik; i svaki R2 je vodik.
13. Spoj prema bilo kojem od patentnih zahtjeva 4-12, naznačen time, da je Q2 (CR10R11)pR12-
14. Spoj iz patentnog zahtjeva 13, naznačen time, da je svaki R10 vodik.
15. Spoj iz patentnog zahtjeva 14, naznačen time, da je svaki R11 vodik.
16. Spoj prema bilo kojem od patentnih zahtjeva 4-12, naznačen time, da je Q2 po izbom supstituiran s cikoalkilalkilom.
17. Spoj prema bilo kojem od patentnih zahtjeva 4-12, naznačen time, da je Q2 po izboru supstituiran s heterocikloalkilom.
18. Spoj iz patentnog zahtjeva 4, naznačen time, da je spoj: 6'-(2-Hidroksi-etil)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(2-Hidroksi-etil)-1-(4-amino-2(R)-hidroksi-butiril)-sizomicin; 6'-(2-Hidroksi-propanol)-1-(4-amino-2(R)-hidroksi-butiril)-sizomicin; 6'-(Metil-pipcridin-4-il)-1-(4-amino-2(R)-hidroksi-butiril)-sizomicin; 6'-(Metil-ciklopropil)-1-(4-amino-2(R)-hidroksi-butiril)-sizomicin; 6'-(3-Amino-propil)-1-(4-amino-2(R)-hidroksi-butiril)-sizomicin; 6'-Metil-ciklopropil-l-(3-amino-2(R)-hidroksi-propionil)-sizomicin; 6'-Metil-pipcridinil-l-(3-amino-2(R)-hidroksi-propionil)-sizomicin; 6'-(2-Hidroksi-etil)-1-(3-amino-2(R)-hidroksi-propionil)-sizomicin; 6'-(2-Hidroksi-propanol)-1-(3-amino-2(R)-hidroksi-propionil)-sizomicin; 6'-(3-Amino-propil)-1-(3-amino-2(R)-hidroksi-propionil)-sizomicin; 6'-(Metil-pipcridin-4-il)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(Metil-ciklopropil)-1-(3-amino-2(S)-hidroksi-propionil)-sizomicin; 6'-(2-Hidroksi-propanol)-1-(3-amino-2(S)-hidroksi-propionil)-sizomicin; 6'-(Metil-pipcridin-4-il)-1-(3-amino-2(S)-hidroksi-propionil)-sizomicin; 6'-(2-Hidroksi-etil)-1-(3-amino-2(S)-hidroksi-propionil)-sizomicin; 6'-(3-Amino-propil)-1-(3-amino-2(S)-hidroksi-propionil)-sizomicin; 6'-(Metil-ciklopropil)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(2-Hidroksi-propanol)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin, 6'-(3-Amino-2-hidroksi-propil)-1-(3-amino-2(S)-hidroksi-propionil)-sizomicin; 6'-(2-Hidroksi-etil)-1 -(2-hidroksi-acetil)-sizomicin; 6'-(3-Amino-propil)-1-(2-amino-etilsulfonamid)-sizomicin; 6'-(2-Hidroksi-propanol)-1-(2-amino-etilsulfonamid)-sizomicin; 6'-(2(S)-Hidroksi-propanol)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(2-Hidroksi-etil)-1-(2-amino-etilsulfonamid)-sizomicin; 6'-(Metil-trans-3-amino-ciklobutil)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(2-Hidroksi-etil)-1-(3-hidroksi-pirolidin-3-il-acetil)-sizomicin; 6'-(2-Hidroksi-4-amino-butil)-1-(3-hidroksi-pirolidin-3-il-acetil)-sizomicin; 6'-(Metil-ciklopropil)-1-(3-hidroksi-azetidin-3-il-acetil)-sizomicin; 6'-(2-Hidroksi-etil)-1-(3-hidroksi-azetidin-3-il-acetil)-sizomicin; 6'-(Metil-(l-hidroksi-3-Metilamino-ciklobutil)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(3-Amino-propil)-1-(3-hidroksi-pirolidin-3-il-acetil)-sizomicin; 6'-(Metil-ciklopropil)-1-(3-hidroksi-pirolidin-3-il-acetil)-sizomicin; 6'-(2-Hidroksi-3-amino-propil)-1-(3-hidroksi-pirolidin-3-il-acetil)-sizomicin; 6'-(3-Amino-propil)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(Metil-pirolidin-2-il)-1-(4-amino-2(S)-hidroksi-butiril)-sizomicin; 6'-(3-Amino-propil)-1-(3-hidroksi-azetidin-3-il-acetil)-sizomicin; 6'-(3-Amino-propil)-1-(l-hidroksi-3-amino-ciklobutil-acetil)-sizomicin; 6'-(Metil-trans-3-amino-ciklobutil)-1-(3-amino-2(S)-hidroksi-propionil)-sizomicin; 6'-(Metil-trans-3-amino-ciklobutil)-1 -(1 -hidroksi-3-amino-ciklobutil-acetil)-sizomicin; 6'-(2-Hidroksi-etil)-1-(l-hidroksi-3-amino-ciklobutil-acetil)-sizomicin; 6'-Metilciklopropil-l-(2-(azetidin-3-il)-2-hidroksi-acetil)-sizomicin; 6'-(Metil-trans-3-amino-ciklobutil)-1-(2-(azetidin-3-il)-2-hidroksi-acetil)-sizomicin; 6'-(2-Hidroksi-etil)-1-(2-(azetidin-3-il)-2-hidroksi-acetil)-sizomicin; 6'-(3-Amino-propil)-1-(2-(azetidin-3-il)-2-hidroksi-acetil)-sizomicin; 6'-(Metil-trans-3-amino-ciklobutil)-1-(3-hidroksi-pirolidin-3-il-acetil)-sizomicin; 6'-(2-Hidroksi-3-amino-propil)-1-(2-(azetidin-3-il)-2-hidroksi-acetil)-sizomicin; ili 6'-(Metil-3-amino-l-hidroksi-ciklobutil)-1-(2-(azetidin-3-il)-2-hidroksi-acetil)-sizomicin.
19. Spoj prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da su Q1 i Q3 različiti od vodika.
20. Spoj iz patentnog zahtjeva 19, naznačen time, da je Q2 vodik.
21. Spoj prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da su Q2 i Q3 različiti od vodika.
22. Spoj iz patentnog zahtjeva 21, naznačen time, da je Q1 vodik.
23. Farmaceutski pripravak, naznačen time, da sadrži spoj iz bilo kojeg od patentnih zahtjeva 1-22 ili stereoizomer, farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
24. Spoj prema bilo kojem od patentnih zahtjeva 1-22 ili pripravak iz patentnog zahtjeva 23, naznačen time, da se koristi za liječenje bakterijske infekcije kod sisavaca kojima je potrebno liječenje.
25. Spoj iz patentnog zahtjeva 4, naznačen time, da je spoj 6'-(2-Hidroksi-etil)-1-(4-amino-2(S)-hidroksi- butiril)-sizomicin.
HRP20170154TT 2007-11-21 2008-11-21 Analozi antibakterijskog aminoglikozida HRP20170154T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98964507P 2007-11-21 2007-11-21
PCT/US2008/084399 WO2009067692A1 (en) 2007-11-21 2008-11-21 Antibacterial aminoglycoside analogs
EP08851633.1A EP2217610B1 (en) 2007-11-21 2008-11-21 Antibacterial aminoglycoside analogs

Publications (1)

Publication Number Publication Date
HRP20170154T1 true HRP20170154T1 (hr) 2017-03-24

Family

ID=40512286

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170154TT HRP20170154T1 (hr) 2007-11-21 2008-11-21 Analozi antibakterijskog aminoglikozida

Country Status (22)

Country Link
US (5) US8383596B2 (hr)
EP (2) EP3150617B1 (hr)
JP (2) JP4986310B2 (hr)
KR (1) KR101296099B1 (hr)
CN (2) CN101868472B (hr)
AU (1) AU2008326297B2 (hr)
BR (1) BRPI0819319B8 (hr)
CA (1) CA2706369C (hr)
CY (1) CY1118915T1 (hr)
DK (1) DK2217610T3 (hr)
EA (1) EA017824B1 (hr)
ES (1) ES2613936T3 (hr)
HR (1) HRP20170154T1 (hr)
HU (1) HUE030523T2 (hr)
IL (1) IL205880A (hr)
LT (1) LT2217610T (hr)
MX (1) MX2010005632A (hr)
PL (1) PL2217610T3 (hr)
PT (1) PT2217610T (hr)
SI (1) SI2217610T1 (hr)
TW (1) TWI425947B (hr)
WO (1) WO2009067692A1 (hr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957507B1 (en) 2005-12-02 2018-10-24 Ionis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
CN101715455A (zh) * 2007-04-10 2010-05-26 尔察祯有限公司 抗菌的1,4,5-取代的氨基糖苷类似物
LT2217610T (lt) * 2007-11-21 2017-02-27 Achaogen, Inc. Antibakteriniai aminoglikozidų analogai
WO2010030690A1 (en) 2008-09-10 2010-03-18 Isis Pharmaceuticals, Inc. Antibacterial 4,6-substituted 6', 6" and 1 modified aminoglycoside analogs
WO2010030704A2 (en) 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010042851A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010042850A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
CA2761756A1 (en) * 2009-05-14 2010-11-18 Achaogen, Inc. Treatment of urinary tract infections with antibacterial aminoglycoside compounds
CA2761674C (en) * 2009-05-14 2016-11-29 Achaogen, Inc. Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds
AR076584A1 (es) * 2009-05-14 2011-06-22 Achaogen Inc Metodo para tratar infeccion bacteriana. regimenes de dosificacion de aminoglicosidos. un aminoglucosido
WO2010132765A2 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010132760A1 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial derivatives of tobramycin
WO2010132768A1 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial derivatives of sisomicin
WO2010132757A2 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010132759A1 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial derivatives of dibekacin
WO2010147836A1 (en) 2009-06-17 2010-12-23 Achaogen, Inc. Combination therapies using antibacterial aminoglycoside compounds
EP2486044A2 (en) 2009-10-09 2012-08-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
CN103282370A (zh) * 2010-11-17 2013-09-04 尔察祯有限公司 抗菌氨基糖苷类类似物
US9238670B2 (en) 2013-03-15 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Aminoglycoside antibiotics with reduced ototoxicity
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
EP3330275A4 (en) 2015-07-30 2018-12-05 Microbial Chemistry Research Foundation Novel aminoglycoside antibiotic effective against multidrug-resistant bacteria
CN107987111A (zh) * 2017-07-07 2018-05-04 朱孝云 抗菌性氘代氨基糖苷类衍生物
WO2019079613A1 (en) * 2017-10-19 2019-04-25 Achaogen, Inc. SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGUES
CN109900816A (zh) * 2017-12-11 2019-06-18 江苏省食品药品监督检验研究院 一种分析注射用硫酸核糖霉素含量及有关物质的高效液相色谱蒸发光散射检测器法
CN108948107B (zh) * 2018-07-30 2020-05-05 山东大学 一种普拉佐米星抗生素的制备方法
WO2020115190A1 (en) 2018-12-05 2020-06-11 Agilebiotics B.V. Novel antibacterial 3"-derivatives of 4,6-disubstituted 2,5-dideoxystreptamine aminoglycoside antibiotics
JP7249438B2 (ja) * 2019-05-30 2023-03-30 卓和薬業集団股▲ふん▼有限公司 抗菌性アミノグリコシド誘導体
CN110878108B (zh) * 2019-06-17 2022-11-11 山东安信制药有限公司 一种普拉佐米星的合成方法
CN110885350A (zh) * 2019-08-28 2020-03-17 山东安信制药有限公司 一种普拉佐米星的制备方法
CN110642907B (zh) * 2019-10-12 2020-11-06 上海博璞诺科技发展有限公司 普拉唑米星或其盐的合成方法
CN111004292A (zh) * 2019-12-19 2020-04-14 卓和药业集团有限公司 庆大霉素衍生物及其制备方法
US20220395555A1 (en) * 2020-06-11 2022-12-15 Boris Farber Derivatives of antibiotics
CN116462721B (zh) * 2023-04-18 2024-02-02 江南大学 抗菌性氨基糖苷衍生物

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA992535A (en) 1972-03-08 1976-07-06 Bristol-Myers Squibb Company Antibiotic derivatives
US3780018A (en) 1972-06-26 1973-12-18 Bristol Myers Co Derivatives of gentamicin c1
US4107424A (en) 1972-10-06 1978-08-15 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai 1-N-[(S)-α-hydroxy-ω-aminoacyl] derivatives of 3',4'-dideoxykanamycin B and 3'-deoxykanamycin B antibiotics
JPS5644076B2 (hr) 1973-07-12 1981-10-16
US4029882A (en) 1974-03-19 1977-06-14 Schering Corporation Selective acylation of the C-1 amino group of aminoglycoside antibiotics
CH606076A5 (hr) 1973-08-06 1978-10-13 Scherico Ltd
JPS554118B2 (hr) 1973-08-29 1980-01-29
JPS5635193B2 (hr) 1973-12-12 1981-08-15
JPS5635195B2 (hr) 1974-01-24 1981-08-15
US4002742A (en) 1974-03-19 1977-01-11 Schering Corporation 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor
AR207582A1 (es) 1974-03-19 1976-10-15 Scherico Ltd Procedimiento para preparar derivados de diaminociclitole
CA1046512A (en) 1974-03-19 1979-01-16 Peter J.L. Daniels Derivatives of diaminocyclitols and method for their preparation
CA1034573A (en) 1974-08-01 1978-07-11 Peter J.L. Daniels Preparation of 1-n-substituted 4,6-di-(aminoglycosyl)-1,3-diaminocyclitols
US4000261A (en) 1974-11-29 1976-12-28 Schering Corporation 5-epi-4,6-di-o-(aminoglycosyl)-2-deoxystreptamines, methods for their manufacture and intermediates useful therein, methods for their use as antibacterial agents and compositions useful therefor
US4000262A (en) 1974-11-29 1976-12-28 Schering Corporation 5-epi-amino and 5-epi-azido-4,6-di-o-(aminoglycosyl)-2,5-dideoxystreptamines 1-n-alkyl-5-epi-amino and 1-n-alkyl-5-epi-azido-4,6-di-o-(aminoglycosyl)-2,5-dideoxystreptamines
IE42179B1 (en) 1974-12-09 1980-06-18 Bristol Myers Co Kanamycin derivatives
US3997524A (en) 1975-05-02 1976-12-14 Schering Corporation Process for the manufacture of 6'-N-alkyl derivatives of sisomicin and verdamicin; novel intermediates useful therein, and novel 6'-N-alkylverdamicins prepared thereby
US4195171A (en) 1975-07-15 1980-03-25 Abbott Laboratories Derivatives of an antibiotic XK-62-2 and process for the production thereof
JPS5239653A (en) 1975-09-25 1977-03-28 Microbial Chem Res Found Process for preparing antibiotics of 3',4'-dideoxykanamycin b derivati ves
SU623524A3 (ru) 1975-12-26 1978-09-05 "Шерико Лтд.," (Фирма) Способ получени 1- -замещенных производных 4,6-ди /аминогликозил/-1,3-диаминоциклитолов или их солей
JPS52153942A (en) 1976-06-16 1977-12-21 Microbial Chem Res Found Preparation of kanamicin c deoxy derivatives and kanamicine c or its deoxy derivatives
NZ184213A (en) 1976-06-16 1980-05-27 Pfizer 2-deoxystreptamine aminoglycosides and antibacterial pharmaceutical compositions
US4230847A (en) * 1976-06-17 1980-10-28 Schering Corporation Aminoglycoside antibiotic compounds
US4136254A (en) 1976-06-17 1979-01-23 Schering Corporation Process of selectively blocking amino functions in aminoglycosides using transition metal salts and intermediates used thereby
US4085208A (en) 1976-06-21 1978-04-18 Schering Corporation Process for preparing 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 1-epimers and 1-N-alkyl derivatives produced thereby; methods for the use of the 1-epimer derivatives as antibacterial agents and compositions useful therefor
JPS5356661A (en) 1976-10-28 1978-05-23 Shionogi & Co Ltd Novel amino glycoside antibiotics derivatives
DE2712160A1 (de) 1977-03-19 1978-09-28 Bayer Ag Pseudotrisaccharide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AR218910A1 (es) 1977-04-28 1980-07-15 Bristol Myers Co Procedimiento para preparar 1-n-(omega-amino-alfa-hidroxialcanoil)canamicinas y las canamicinas a o b polisililadas obtenidas en dicho procedimiento como in-intermediarios
US4347354A (en) 1977-04-28 1982-08-31 Bristol-Myers Company Preparation of 1-N-[ω-amino-α-hydroxyalkanoyl]aminoglycoside polysilylated antibiotics and products obtained therefrom
CA1105452A (en) 1977-04-28 1981-07-21 Martin J. Cron PREPARATION OF 1-N-[.omega.-AMINO-.alpha.- HYDROXYALKANOYL]AMINOGLYCOSIDE ANTIBIOTICS
US4190722A (en) 1977-06-10 1980-02-26 Bayer Aktiengesellschaft 4,6-Di-O-(aminoglycosyl)-1,3-diaminocyclitols, process for their production and their use
US4212859A (en) 1977-06-24 1980-07-15 Schering Corporation 2'-Hydroxy-2'-desamino-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, method for their use as antibacterial agents, and compositions useful therefor
US4282350A (en) 1977-08-05 1981-08-04 Schering Corporation Selective 3"-N-acylation of 1,3"-di-N-unprotected-poly-N-protected-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols
DK308878A (da) 1977-08-18 1979-02-19 Pfizer Aminoglyosidderivater og fremgangsmaader til deres fremstilling
DE2737264A1 (de) 1977-08-18 1979-03-01 Bayer Ag Pseudotrisaccharide
CA1105455A (en) * 1977-09-19 1981-07-21 Junji Irisawa Aminoglycoside derivatives
JPS5446770A (en) 1977-09-19 1979-04-12 Shionogi & Co Ltd Novel aminoglycoside derivatives
JPS5461151A (en) 1977-10-25 1979-05-17 Shionogi & Co Ltd Novel aminoglycoside derivative
DE2753769A1 (de) 1977-12-02 1979-06-13 Bayer Ag 1-n-4,6-di-o-(aminoglykosyl)-1,3- diamino-cyclitol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung
JPS5492951A (en) 1977-12-29 1979-07-23 Shionogi & Co Ltd Novel aminoglycoside derivative
US4169141A (en) 1978-01-30 1979-09-25 Shering Corporation 1-Peptidyl derivatives of di-O-aminoglycosyl-1,3-diaminocyclitol antibacterial agents
US4337335A (en) 1978-05-18 1982-06-29 Schering Corporation Transition metal salt complexes of polyamino organic compounds
JPS55329A (en) 1978-06-19 1980-01-05 Kyowa Hakko Kogyo Co Ltd Novel xk-62-4 derivative
DE2832268A1 (de) 1978-07-22 1980-01-31 Bayer Ag Pseudotrisaccharide
JPS5538345A (en) 1978-09-11 1980-03-17 Shionogi & Co Ltd Novel aminoglycoside derivative
DE2936120A1 (de) 1978-09-14 1980-03-27 Sandoz Ag Neue aminoglykoside, deren herstellung und deren verwendung als antimikrobielle mittel
JPS5540621A (en) 1978-09-14 1980-03-22 Shionogi & Co Ltd Novel aminoglycoside derivative
DE2921973A1 (de) 1979-05-30 1980-12-11 Bayer Ag Sisomicin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2924659A1 (de) 1979-06-19 1981-01-22 Bayer Ag Pseudotrisaccharide, ihre herstellung und verwendung als arzneimittel
DE2928183A1 (de) * 1979-07-12 1981-01-29 Bayer Ag 1-n-alkylsisomicin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3000841A1 (de) 1980-01-11 1981-07-16 Bayer Ag, 5090 Leverkusen Isolierung und reinigung von aminoglycosid-antibiotiaka
DE3100739A1 (de) 1981-01-13 1982-08-26 Bayer Ag, 5090 Leverkusen Pseudotrisaccharide, verfahren zu deren herstellung, deren verwendung als arzneimittel und die pseudotrisaccharide enthaltende arzneimittel sowie deren herstellung
DE3101376A1 (de) 1981-01-17 1982-09-02 Bayer Ag, 5090 Leverkusen Sisomicin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3108068A1 (de) 1981-03-04 1982-09-16 Bayer Ag, 5090 Leverkusen N-methansulfonsaeuren und alkali-n-methansulfonate von sisomicin, gentamicin und deren derivaten, verfahren zu ihrer herstellung, die neuen verbindungen enthaltende arzneimittel und ihre verwendung als antibiotika
DE3206725A1 (de) 1981-05-13 1982-12-02 Merck Patent Gmbh, 6100 Darmstadt Schwer loesliche salze von aminoglykosidantibiotika
DE3405326A1 (de) 1984-02-15 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue aminglykoside, verfahren zu ihrer herstellung und ihre verwendung
JPH01254694A (ja) 1988-04-05 1989-10-11 Microbial Chem Res Found ５−エピネチルミシン及びその製造法
US5900406A (en) 1991-07-09 1999-05-04 Nzym, Inc. Use of antibiotics of the type 2-deoxystreptamine substituted with aminosugars to inhibit growth of microorganisms containing group I introns
CA2147605A1 (en) 1992-10-23 1994-05-11 Michael R. Green Small molecule inhibition of rna/ligand binding
US5534408A (en) 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
CN1040177C (zh) 1993-04-23 1998-10-14 江苏省微生物研究所 一种含1-N-乙基庆大霉素C1a或其盐的药用制剂及制备方法
KR0139021B1 (ko) 1995-02-09 1998-04-30 김은영 1-엔(n)-에틸시소마이신의 제조방법
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
CN1156488C (zh) 2001-12-18 2004-07-07 国家药品监督管理局四川抗菌素工业研究所 小诺霉素新衍生物、制备方法和医药用途
US20070161581A1 (en) * 2004-01-21 2007-07-12 Nobuto Minowa Novel aminoglycoside antibiotics effective against methicillin resistant staphylococcus auerus (mrsas)
WO2006052930A1 (en) 2004-11-05 2006-05-18 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
WO2007028012A2 (en) 2005-09-01 2007-03-08 Isis Pharmaceuticals, Inc. Antibacterial 6'-n-modified 4,5-substituted aminoglycoside analogs
EP1957507B1 (en) 2005-12-02 2018-10-24 Ionis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8153166B2 (en) 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
CN101715455A (zh) 2007-04-10 2010-05-26 尔察祯有限公司 抗菌的1,4,5-取代的氨基糖苷类似物
LT2217610T (lt) 2007-11-21 2017-02-27 Achaogen, Inc. Antibakteriniai aminoglikozidų analogai
WO2010030704A2 (en) 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010030690A1 (en) 2008-09-10 2010-03-18 Isis Pharmaceuticals, Inc. Antibacterial 4,6-substituted 6', 6" and 1 modified aminoglycoside analogs
WO2010042851A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010042850A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
CA2761674C (en) 2009-05-14 2016-11-29 Achaogen, Inc. Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds
AR076584A1 (es) 2009-05-14 2011-06-22 Achaogen Inc Metodo para tratar infeccion bacteriana. regimenes de dosificacion de aminoglicosidos. un aminoglucosido
CA2761756A1 (en) 2009-05-14 2010-11-18 Achaogen, Inc. Treatment of urinary tract infections with antibacterial aminoglycoside compounds
WO2010132757A2 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010132760A1 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial derivatives of tobramycin
WO2010132765A2 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010132759A1 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial derivatives of dibekacin
WO2010132768A1 (en) 2009-05-15 2010-11-18 Achaogen, Inc. Antibacterial derivatives of sisomicin
WO2010147836A1 (en) 2009-06-17 2010-12-23 Achaogen, Inc. Combination therapies using antibacterial aminoglycoside compounds
WO2011044498A1 (en) 2009-10-09 2011-04-14 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2011044538A1 (en) 2009-10-09 2011-04-14 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2011044502A1 (en) 2009-10-09 2011-04-14 Achaogen, Inc. Antibacterial aminoglycoside analogs
EP2486044A2 (en) 2009-10-09 2012-08-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2011044503A1 (en) 2009-10-09 2011-04-14 Achaogen, Inc. Antibacterial aminoglycoside analogs
CN103282370A (zh) 2010-11-17 2013-09-04 尔察祯有限公司 抗菌氨基糖苷类类似物

Also Published As

Publication number Publication date
KR101296099B1 (ko) 2014-02-26
US20160368942A1 (en) 2016-12-22
MX2010005632A (es) 2010-09-10
US8383596B2 (en) 2013-02-26
CA2706369A1 (en) 2009-05-28
US20130217642A1 (en) 2013-08-22
PT2217610T (pt) 2017-02-10
US20100099661A1 (en) 2010-04-22
US20200317709A1 (en) 2020-10-08
CN103360440B (zh) 2016-08-31
TWI425947B (zh) 2014-02-11
BRPI0819319B1 (pt) 2019-01-15
EA017824B1 (ru) 2013-03-29
CN103360440A (zh) 2013-10-23
EP3150617A1 (en) 2017-04-05
HUE030523T2 (en) 2017-05-29
TW200927146A (en) 2009-07-01
JP2011219498A (ja) 2011-11-04
WO2009067692A1 (en) 2009-05-28
BRPI0819319B8 (pt) 2021-05-25
EP2217610A1 (en) 2010-08-18
CY1118915T1 (el) 2018-01-10
US11117915B2 (en) 2021-09-14
JP4986310B2 (ja) 2012-07-25
ES2613936T3 (es) 2017-05-29
DK2217610T3 (en) 2017-02-13
US9266919B2 (en) 2016-02-23
CN101868472B (zh) 2013-05-29
IL205880A0 (en) 2010-11-30
SI2217610T1 (sl) 2017-03-31
US20150045317A1 (en) 2015-02-12
US9688711B2 (en) 2017-06-27
EP2217610B1 (en) 2016-11-02
CN101868472A (zh) 2010-10-20
IL205880A (en) 2013-10-31
EA201070597A1 (ru) 2010-12-30
AU2008326297B2 (en) 2012-11-08
LT2217610T (lt) 2017-02-27
EP3150617B1 (en) 2020-04-08
JP2011504508A (ja) 2011-02-10
AU2008326297A1 (en) 2009-05-28
PL2217610T3 (pl) 2017-04-28
CA2706369C (en) 2014-03-25
BRPI0819319A2 (pt) 2015-05-12
KR20100110297A (ko) 2010-10-12
US8822424B2 (en) 2014-09-02

Similar Documents

Publication Publication Date Title
HRP20170154T1 (hr) Analozi antibakterijskog aminoglikozida
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
JP2011219498A5 (hr)
ME02373B (me) Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
HRP20090627T1 (hr) Inhibitori hcv ns3 proteaze
AR029489A1 (es) Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
HRP20140494T1 (hr) Makrocikliäśki inhibitori serin proteaze hepatitisa c
HRP20241482T1 (hr) Kratki peptidni spoj prolina s modificiranim prstenom i njegova uporaba
SI2834239T1 (en) Heterobicyclic compounds as inhibitors of beta-lactamase
HRP20230854T1 (hr) Fap-aktivirana terapeutska sredstva i s njima povezane uporabe
HRP20220231T1 (hr) Spojevi i postupci za liječenje bakterijskih infekcija
HRP20160623T1 (hr) Inhibitori proteinske kinaze
EA201300494A1 (ru) Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
HRP20161092T1 (hr) Cdk inhibitori
HRP20120523T1 (hr) Inhibitori virusa hepatitisa c
HRP20170634T4 (hr) Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
HRP20130942T1 (hr) Aminodiazepini kao modulatori toll-u sliäśnih receptora
AR037233A1 (es) Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
HRP20160083T1 (hr) Makrocikliäśki inhibitori serinske proteaze virusa hepatitisa c izvedeni iz prolina
BR112015010244A8 (pt) compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso
PA8795301A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
HRP20030565B1 (hr) Nukleozid derivati kao inhibitori rna-ovisne rna virusne polimeraze
HRP20200812T1 (hr) Protutijela protiv teihonske kiseline staničnog zida i konjugati
BR112015009798A2 (pt) compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa